ADMA Biologics Refutes Short-Seller Report Over Disclosed Short Position
ADMA Biologics on March 25 rebutted a short-seller report by Culper Research, noting the firm’s disclosed short position and labeling its assertions speculative and false. The company affirmed full compliance with SEC regulations and U.S. GAAP in reporting its financial and operating results and is reviewing the report’s claims.
1. Short-Seller Report Details
Culper Research’s March 24 report claimed various operational and financial deficiencies at ADMA Biologics, relying on unidentified sources and asserting potential risks to manufacturing and commercialization. The report also disclosed that Culper holds a short position in ADMA stock, positioning itself to profit from any share decline.
2. ADMA’s Rebuttal and Compliance
On March 25, ADMA Biologics issued a formal response contesting the report’s accuracy, labeling its assertions as speculative, misleading and false. The company affirmed its full compliance with U.S. Securities and Exchange Commission regulations and U.S. GAAP in all financial and public disclosures.
3. Next Steps and Review Process
ADMA’s Board of Directors has initiated a thorough review of the report’s claims to assess any necessary corrective measures. The company has not announced operational changes while the assessment is ongoing and continues standard manufacturing and marketing activities.